<DOC>
	<DOCNO>NCT00002319</DOCNO>
	<brief_summary>To evaluate safety effectiveness Stealth liposomal doxorubicin hydrochloride ( DOX-SL ) long-term treatment AIDS-related Kaposi 's sarcoma ( KS ) patient previously good response DOX-SL control study limit duration , KS discontinue treatment another Kaposi 's sarcoma therapy inadequate efficacy unacceptable toxicity . To provide define protocol Kaposi 's sarcoma patient DOX-SL therapy indicate .</brief_summary>
	<brief_title>A Study DOX-SL Treatment AIDS-Related Kaposi 's Sarcoma</brief_title>
	<detailed_description>Patients receive DOX-SL every 3 week maximum 20 cycle ( include cycle previous DOX-SL study ) . KS lesion evaluate prior administration treatment , end final treatment cycle , 4 week follow end final treatment . Patients respond follow every 2 month 1 year . Study treatment may interrupt 4 month complete response , development opportunistic infection , adverse drug effect .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Prophylaxis PCP , cryptococcal , herpes infection , antiretroviral therapy provide dos stable least 1 month . Maintenance therapy tuberculosis , fungal , herpes infection . Therapy new episode tuberculosis , fungal , herpes infection except potentially myelotoxic chemotherapy . Foscarnet ganciclovir CMV infection . Colony stimulate factor erythropoietin . Patients must : Moderate severe AIDSrelated Kaposi 's sarcoma . Documented antiHIV antibody . No active opportunistic infection mycobacteria , cytomegalovirus , toxoplasma , Pneumocystis carinii , microorganism ( treatment myelotoxic drug ) . NOTE : Eligible KS patient include discontinue therapy control arm DOXSL KS study side effect inadequate efficacy OR KS patient DOXSL believe indicated . Patients must eligible Liposome Technology protocols compare DOXSL establish therapy . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Clinically significant cardiac disease . Confusion disorientation . Concurrent Medication : Excluded : Other cytotoxic cancer chemotherapy . Patients follow prior condition exclude : Prior neoplasms treat extensive chemotherapy , investigator 's opinion , lead irreversibly compromise marrow function . History idiosyncratic allergic reaction anthracyclines . History major psychiatric illness . Prior Medication : Excluded within past 4 week : Cytotoxic chemotherapy ( qualify Liposome Technology protocol ) . Interferon treatment . Prior Treatment : Excluded within past 3 week : Radiation electron beam therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 1996</verification_date>
	<keyword>Sarcoma , Kaposi</keyword>
	<keyword>Liposomes</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Drug Carriers</keyword>
</DOC>